Chung-Han Lee, Ph.D.
Affiliations: | 2009 | University of Michigan, Ann Arbor, Ann Arbor, MI |
Area:
Molecular BiologyGoogle:
"Chung-Han Lee"Mean distance: 30533.1
Parents
Sign in to add mentor| Kunliang Guan | grad student | 2009 | University of Michigan | |
| (Glucose starvation induces apoptosis of TSC-/- cells in a p53-dependent manner.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Ma J, Del Balzo L, Walch H, et al. (2024) Clinical Outcomes and Targeted Genomic Analysis of Renal Cell Carcinoma Brain Metastases Treated with Stereotactic Radiosurgery. European Urology Oncology |
| Fitzgerald KN, Lee CH, Voss MH, et al. (2024) Cabozantinib Plus Nivolumab in Patients with Non-Clear Cell Renal Cell Carcinoma: Updated Results from a Phase 2 Trial. European Urology |
| Lee CH, Yogesh Shah A, Rao A, et al. (2024) Lenvatinib plus Pembrolizumab Following Immune Checkpoint Inhibitor Treatment in Patients with Metastatic Clear Cell Renal Cell Carcinoma: Results from Study 111/KEYNOTE-146. European Urology |
| Reese SW, Eismann L, White C, et al. (2023) Surgical outcomes of cytoreductive nephrectomy in patients receiving systemic immunotherapy for advanced renal cell carcinoma. Urologic Oncology |
| Kotecha RR, Doshi SD, Knezevic A, et al. (2023) A Phase 2 Trial of Talazoparib and Avelumab in Genomically Defined Metastatic Kidney Cancer. European Urology Oncology |
| Albiges L, Gurney H, Atduev V, et al. (2023) Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial. The Lancet. Oncology |
| Hahn AW, Kotecha RR, Viscuse PV, et al. (2023) Cytoreductive Nephrectomy for Patients with Metastatic Sarcomatoid and/or Rhabdoid Renal Cell Carcinoma Treated with Immune Checkpoint Therapy. European Urology Focus |
| McGregor B, Geynisman DM, Burotto M, et al. (2023) A Matching-adjusted Indirect Comparison of Nivolumab Plus Cabozantinib Versus Pembrolizumab Plus Axitinib in Patients with Advanced Renal Cell Carcinoma. European Urology Oncology |
| Fitzgerald KN, Motzer RJ, Lee CH. (2022) Adjuvant therapy options in renal cell carcinoma - targeting the metastatic cascade. Nature Reviews. Urology |
| Fitzgerald KN, Duzgol C, Knezevic A, et al. (2022) Progression-free Survival After Second Line of Therapy for Metastatic Clear Cell Renal Cell Carcinoma in Patients Treated with First-line Immunotherapy Combinations. European Urology |